{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.19","upperLimit":"3.75","value":"3.65"},{"groupId":"OG001","lowerLimit":"3.68","upperLimit":"5.32","value":"3.78"},{"groupId":"OG002","lowerLimit":"2.79","upperLimit":"4.86","value":"3.65"},{"groupId":"OG003","lowerLimit":"3.75","upperLimit":"5.49","value":"4.07"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"389"},{"groupId":"OG001","value":"393"},{"groupId":"OG002","value":"153"},{"groupId":"OG003","value":"389"}],"units":"Participants"}],"description":"PFS (per Response Evaluation Criteria in Solid Tumors, version 1.1 \\[RECIST 1.1\\] using Investigator assessments) was defined as the time from the date of randomization until the date of objective disease progression or death by any cause in the absence of progression, regardless of whether the patient withdrew from study treatment or received another anticancer therapy prior to progression. Progression (i.e., PD) was defined as a at least 20% increase in the sum of diameters of TLs, taking as reference the smallest previous sum of diameters (nadir) - this includes the baseline sum if that is the smallest on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm from nadir.","dispersionType":"95% Confidence Interval","groups":[{"description":"Durvalumab 1500 mg every 4 weeks (Q4W)","id":"OG000","title":"Durva 1500 mg"},{"description":"Tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W","id":"OG001","title":"Treme 300 mg x1 Dose + Durva 1500 mg"},{"description":"Tremelimumab 75 mg Q4W × 4 doses + durvalumab 1500 mg Q4W","id":"OG002","title":"Treme 75 mg x4 Doses + Durva 1500 mg"},{"description":"Sorafenib 400 mg twice daily (BID)","id":"OG003","title":"Sora 400 mg"}],"paramType":"MEDIAN","populationDescription":"The FAS included all participants who were randomized. T75+D arm was closed during study.","reportingStatus":"POSTED","timeFrame":"Tumor scans performed at baseline, every 8 weeks for the first 48 weeks following randomization, and every 12 weeks thereafter until RECIST 1.1-defined progression. Assessed up to DCO (27Aug2021, to a maximum of approximately 46 months)","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}